This question is especially pertinent given the role of NAD+ in maintaining cancer cell metabolism (Navas et al, 2023; Tateishi et al, 2017), and the development of NAD+ biosynthetic inhibitors targeting nicotinamide phosphoribosyltransferase (NAMPT) to treat cancer (Tateishi et al, 2017; von Heideman et al, 2010). Here, NAMPT is linked to cancer.